<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Jasper Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/jasper-therapeutics-inc</link>
<description>Latest news and press releases for Jasper Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/jasper-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358cae78dffbe2df100932.webp</url>
<title>Jasper Therapeutics Inc</title>
<link>https://6ix.com/company/jasper-therapeutics-inc</link>
</image>
<item>
<title>Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on</description>
</item>
<item>
<title>Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-to-present-at-46th-annual-td-cowen-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-to-present-at-46th-annual-td-cowen-healthcare-conference</guid>
<pubDate>Tue, 24 Feb 2026 21:30:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston</description>
</item>
<item>
<title>Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-positive-updated-120000640</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-positive-updated-120000640</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study B</description>
</item>
<item>
<title>Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-appoints-jeet-mahal-213000416</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-appoints-jeet-mahal-213000416</guid>
<pubDate>Wed, 07 Jan 2026 21:30:00 GMT</pubDate>
<description>Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases s</description>
</item>
<item>
<title>Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-positive-preliminary-120000305</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-positive-preliminary-120000305</guid>
<pubDate>Tue, 02 Dec 2025 12:00:00 GMT</pubDate>
<description>Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with drug product utilized Jasper to host conference call and webinar today at 8:00 a.m. ET REDWOOD CITY, Calif., Dec. 02, 2025 (</description>
</item>
<item>
<title>Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-host-investor-webinar-213000842</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-host-investor-webinar-213000842</guid>
<pubDate>Mon, 01 Dec 2025 21:30:00 GMT</pubDate>
<description>Webinar to be held Tuesday, December 2nd, at 8:00 am ETREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the Company will host a webinar to present fi</description>
</item>
<item>
<title>Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-third-quarter-130000490</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-third-quarter-130000490</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2025 and provided a corporate update. “With a number of data events ex</description>
</item>
<item>
<title>Jasper Therapeutics to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-present-upcoming-investor-130000927</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-present-upcoming-investor-130000927</guid>
<pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following upcoming investor conferences: UBS Global Healthcare Conference 2025Conf</description>
</item>
<item>
<title>Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-announces-pricing-of-dollar30-million-public-offering-of-common-stock-pre-funded-warrants-and-common-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-announces-pricing-of-dollar30-million-public-offering-of-common-stock-pre-funded-warrants-and-common-warrants</guid>
<pubDate>Fri, 19 Sep 2025 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused</description>
</item>
<item>
<title>Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-announces-proposed-public-200800511</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-announces-proposed-public-200800511</guid>
<pubDate>Thu, 18 Sep 2025 20:08:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced today that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of</description>
</item>
<item>
<title>Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-second-quarter-200500579</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-second-quarter-200500579</guid>
<pubDate>Wed, 13 Aug 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended June 30, 2025 and provided a corporate update. “The compelling results we are genera</description>
</item>
<item>
<title>Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-announces-corporate-reorganization-120000981</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-announces-corporate-reorganization-120000981</guid>
<pubDate>Wed, 09 Jul 2025 12:00:00 GMT</pubDate>
<description>Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic</description>
</item>
<item>
<title>Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-clinical-data-113000214</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-clinical-data-113000214</guid>
<pubDate>Mon, 07 Jul 2025 11:30:00 GMT</pubDate>
<description>8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks Results from the 240mg Q8W and the 240mg followed by 180mg Q8W cohorts appear to be confounded by issues with one drug product lot ETESIAN study in asthma to be stopped due to same drug product lot issue No grade 3 or higher treatment related adverse events reported Compan</description>
</item>
<item>
<title>Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-positive-data-140000946</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-positive-data-140000946</guid>
<pubDate>Sat, 14 Jun 2025 14:00:00 GMT</pubDate>
<description>11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper T</description>
</item>
<item>
<title>Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-announces-briquilimab-presentations-120000612</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-announces-briquilimab-presentations-120000612</guid>
<pubDate>Tue, 03 Jun 2025 12:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasg</description>
</item>
<item>
<title>Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-first-quarter-200500445</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-first-quarter-200500445</guid>
<pubDate>Mon, 12 May 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2025 and provided a corporate update. “During the first quarter of 2025 we made great</description>
</item>
<item>
<title>Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-presents-clinical-preclinical-174500230</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-presents-clinical-preclinical-174500230</guid>
<pubDate>Sat, 01 Mar 2025 17:45:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at</description>
</item>
<item>
<title>Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-announces-breaking-briquilimab-130000708</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-announces-breaking-briquilimab-130000708</guid>
<pubDate>Fri, 28 Feb 2025 13:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced a late-breaking oral presentation of briquilimab data from the Phase 1b/2a BEACON in CSU study at the 2025 AAD Annual Meeting, b</description>
</item>
<item>
<title>Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-fourth-quarter-130000574</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-reports-fourth-quarter-130000574</guid>
<pubDate>Thu, 27 Feb 2025 13:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2024 and provided a corporate update. “The past year has been</description>
</item>
<item>
<title>Jasper Therapeutics to Present at Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-present-upcoming-march-213000589</link>
<guid isPermaLink="true">https://6ix.com/company/jasper-therapeutics-inc/news/jasper-therapeutics-present-upcoming-march-213000589</guid>
<pubDate>Tue, 25 Feb 2025 21:30:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following investor conferences in March. TD Cowen 45th Annual Healthcare Confere</description>
</item>
</channel>
</rss>